Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke

• DOI: 10.1021/acsami.8b09423
• Publication Date: 2018-09-07T20:10:20Z
• Authors: Jiangnan Hu; Shengwei Huang; Lu Zhu; Weijie Huang; Yiping Zhao; Kunlin Jin; Qichuan ZhuGe
• Keywords: Thrombolytic drug; Fibrinolytic agent; T-plasminogen activator; Stroke

Tissue plasminogen activator (tPA) is the only FDA approved thrombolytic drug for acute ischemic stroke but concerns regarding its limitations remain. Here, we developed a new strategy by incorporating tPA into porous magnetic iron oxide (Fe3O4)-microrods (tPA-MRs) targeted therapy in induced distal middle cerebral artery occlusion. We showed that intra-arterial injection of tPA-MRs could target blood clot vivo under guidance an external magnet, where was subsequently released at site embolism. When applied with rotating field, significantly improved not mass transport tPA-clot reaction, also mechanically disrupted network, which thus increased interaction and penetration tPA. Importantly, intravenously injected MRs be discharged from kidney, function liver kidney were damaged different durations after administration tPA-MRs. Our data suggest overcome alone, may just treatment have majorly impact on other thrombotic diseases.